Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

By M. E. C. Lutsiak, R. Semnani, R. De Pascalis, S. Kashmiri, J. Schlom, H. Sabzevari. Blood, 2005

985 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/b20a61d4aaac416306d1c6a376df4b3db33f0c6c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Munn
2. Guido Kroemer
3. L. Zitvogel
4. A. Mellor
5. George Coukos
6. G. Freeman
7. M. Azuma
8. M. Pittet

Citations in the corpus

• T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis (2012, background): “death, and it has been suggested that Tregs are more sensitive to cyclophosphamide-induced apoptosis (55).”
• Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016, background): “Cyclophosphamide has been shown to decrease Th2 regulatory T-cells without decreasing circulating Th1 immune response at low doses [49].”
• Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy (2008, background): “Cyclophosphamide has been shown in preclinical studies to enhance cancer vaccine eYciency presumably by decreasing the number of regulatory T cells [20, 21].”
• Regulatory T cells in cancer. (2006, background): “Low-dose cyclophosphamide not only decreases numbers of Treg cells but also leads to decreased function, enhanced apoptosis and decreased homeostatic proliferation.(59) This suggests that cyclophosphamide might be successfully integrated into chemo-immunotherapy as recently shown by Dudley et al.”
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (2007, background): “Low dosing of CTX not only decreases the number, but also inhibits the suppressive function of Treg [12, 13].”
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. (2007, background): “Certain chemotherapeutic drugs such as cyclophosphamide have been reported to partially reduce the number and/or function of Tregs (30, 31).”
• Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016, positive): “Because Cyc can suppress Treg cells (Ghiringhelli et al., 2004; Lutsiak et al., 2005), Oxa-Cyc might promote antitumor responses by acting on Treg cells directly.”